Navigation Links
GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
Date:12/16/2009

PARSIPPANY, N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc [GSK] (NYSE: GSK) and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.

Cold sores are a prevalent condition affecting approximately 20% of the adult population in the US. GSK has established Abreva® as the leading cold sore treatment with a greater than 50% share, gaining two share points in the prior 12 months. Abreva is the only OTC medicine approved by the US Food & Drug Administration that is proven to shorten cold sore healing time.

NanoBio has completed two Phase 2 clinical trials of NB-001, demonstrating clear efficacy and a good safety profile in patients and plans to enter Phase 3 testing soon.

Under the terms of the agreement, NanoBio will receive an upfront payment of $14.5 million, and is eligible to receive additional milestone payments of up to $40 million plus single digit royalties on future sales.

"I am pleased to announce this partnership with GSK as it will enable the development and commercialization of NB-001 to its fullest potential," said James R. Baker, Jr., MD, NanoBio's CEO and founder. "GSK's demonstrated leadership in developing and marketing consumer healthcare products, including the leading product for the treatment of herpes labialis, makes them the ideal partner for NB-001. On a broader scale, this partnership further validates the promise of our proprietary platform technology, and its potential use in a wide range of dermatological and anti-i
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
2. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
3. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
4. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
5. GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
6. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
7. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
8. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
9. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
10. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
11. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NEW YORK and PLAINSBORO, ... Nordisk announced today its support of the National ... in Care , which provides support to people ... the physical and psychosocial challenges that can impede ... of six modules, Communication With Your Provider ...
(Date:9/18/2014)... and MELBOURNE, Australia , Sept. ... Biopharma today announced the appointments of Dr. Ashraf ... D.V.M ., M.S., to its Board of Directors. Dr. ... Affairs Finance at Genentech and Chief Financial Officer for ... as Vice President and Global Head of Business Development ...
(Date:9/18/2014)... NEW YORK , Sept. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... James to the position of  Senior Director of ... Clinical Research, Mr. James has established and led successful ... Europe , to facilitate the clinical development ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Egenix, Inc. -- Donald Fresne, CEO ... appointment of Nils Bergenhem, PhD as President and ... of drug development experience to the company and ... between equally-sized companies, as well as between biotech ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) An audio webcast of the ... Relations portion of the CVS Caremark Web site for ...
Cached Medicine Technology:Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc. 2CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Ottawa (September 18, 2014) A new expert ... released today by the Council of Canadian Academies, ... medicines for children. Each year about half of ... prescription drug. Much of this prescribing is done ... use), creating potential health risks., Children have historically ...
(Date:9/18/2014)... study analyses the survival rates in Spain of newborns with ... survival under 23 weeks is ,exceptional, although other factors such ... Experts from the Spanish Society of Neonatology have studied the ... under 26 weeks, taking into account that a newborn carried ... data have been drawn from the national database that gathers ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Improving medicines for children in Canada 2Health News:The viability of premature babies is minimal at 22 weeks' gestation 2
... test doesn,t single out those at high risk of trouble, ... screening for coronary artery disease is of no value for ... a new study finds. , Screening is expensive, at $1,000 ... 2 diabetes who had no symptoms of heart disease did ...
... Record 1,960 Eye and Tissue Donors in 2008 ... OneLegacy, the non-profit, federally designated organ and tissue ... area, has within the last year become the ... tens of thousands in need of cornea, bone, ...
... scientists at Beth Israel Deaconess Medical Center (BIDMC) have ... part of their 2009 Creativity Awards program, which supports ... prostate cancer. , The one-year awards were made ... with BIDMC the only institution in New England to ...
... April 14 While the number of ... the registry still only includes 38 percent of licensed ... Life America this year. Yet, according to a ... their decision to donate honored, even if their family ...
... Medical Plans, Inc., a leading provider-sponsored health insurer, covering ... announced an innovative Fracture Protection Pilot Program, in cooperation ... of Actonel, a prescription drug for the treatment and ... Alliance for Better Bone Health will cover the average ...
... (Nasdaq: ROCM ) will announce quarterly results after ... Company will then hold a quarterly conference call to discuss ... p.m. central time (5:00 p.m. eastern time).This call is being ... website at www.rocm.com . To listen ...
Cached Medicine News:Health News:Heart Screening Not Effective for Type 2 Diabetics 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 3Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 4Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 2Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 4Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2